Novartis Ag Adr (NVS)

Jan 20, 2025

Pain Management Therapeutics Market Is Expected To Reach Revenue Of USD 120.7 Bn By 2033, At 3.9% CAGR: Dimension Market Research. - GlobeNewswire Inc.

Jan 20, 2025

Jan 17, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Jan 17, 2025

Jan 10, 2025

Saudi Arabia Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 10, 2025

Jan 09, 2025

South Korea Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025

Jan 09, 2025

Thailand Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025

Jan 09, 2025

The United States Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025

Jan 09, 2025

The UAE Pancreatic Cancer Treatment Market Size & Outlook, 2030 - Grand View Research

Jan 09, 2025

Jan 06, 2025

Weekly Upgrades and Downgrades - InvestorPlace

Jan 06, 2025

Dec 19, 2024

Communiqué de presse - GlobeNewswire Inc.

Dec 19, 2024

Dec 17, 2024

Are Investors Undervaluing Novartis (NVS) Right Now? - Yahoo Finance

Dec 17, 2024

Dec 13, 2024

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart

Dec 13, 2024

Dec 13, 2024

Novartis: Time To Increase (NYSE:NVS) - Seeking Alpha

Dec 13, 2024

Dec 09, 2024

Glaucoma Therapeutics Strategic Industry Report 2024 - GlobeNewswire Inc.

Dec 09, 2024

Dec 05, 2024

5 high-yielding stocks that best reflect the UN’s Sustainable Development Goals - Equities News

Dec 05, 2024

Dec 04, 2024

Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity - Barchart

Dec 04, 2024

Dec 04, 2024

5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals - Morningstar

Dec 04, 2024

Nov 22, 2024

Novartis Raises Sales Outlook For Mid-Term, Acquires Kate Therapeutics - Barchart

Nov 22, 2024

Nov 21, 2024

Addressing unmet needs for inherited neuromuscular diseases - Novartis

Nov 21, 2024

Nov 20, 2024

Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets

Nov 20, 2024

Nov 18, 2024

Canada Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research

Nov 18, 2024

Nov 18, 2024

Thailand Antifungal Drugs Market Size & Outlook, 2023-2030 - Grand View Research

Nov 18, 2024

Nov 15, 2024

MEDIA STATEMENTNovartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™ - Barchart

Nov 15, 2024

Nov 06, 2024

Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance

Nov 06, 2024

Nov 01, 2024

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Nov 01, 2024

Oct 29, 2024

Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar

Oct 29, 2024

Oct 29, 2024

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript - Barchart

Oct 29, 2024

Oct 29, 2024

Gene Therapy - Novartis

Oct 29, 2024

Oct 29, 2024

Chemical Biology in Biomedical Research - Novartis

Oct 29, 2024

Oct 29, 2024

Radioligand therapy: delivering now, building for the future - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis at ASH - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook - Yahoo Finance

Oct 29, 2024

Oct 29, 2024

Novartis 2022 Financial Results - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis Financial Results – Q2 2023 - Novartis

Oct 29, 2024

Oct 29, 2024

Translational medicine research at Novartis - Novartis

Oct 29, 2024

Oct 29, 2024

Novartis Financial Results – Q2 2024 - Novartis

Oct 29, 2024

Oct 29, 2024

Inclusivity - Novartis

Oct 29, 2024